These findings suggest that PPARγ activated by PPARγ ligand prevents hepatic fibrosis through inhibiting hepatic stellate cell activation and thus contributes to the pathological improvements for NASH. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.